(2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)penta-2,4-dien-1-amine | 43219-39-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)penta-2,4-dien-1-amine
• 英文别名: 3-methyl-5t-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2t,4-dienylamine；(2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohexen-1-yl)penta-2,4-dien-1-amine
• CAS: 43219-39-2
• 化学式: C₁₅H₂₅N
• 分子量: 219.37
• InChiKey: BHNHKIIFOGCDIQ-ANKZSMJWSA-N

物化性质

• 沸点：
  330.4±11.0 °C(Predicted)
• 密度：
  0.927±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)penta-2,4-dien-1-amine 在 manganese(IV) oxide 、 potassium amide 、 Petroleum ether 作用下， 生成 维A酸
  参考文献：
  名称：

  Matsui et al., Journal of Vitaminology, 1958, vol. 4, p. 190,192

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 作用下， 生成 (2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)penta-2,4-dien-1-amine
  参考文献：
  名称：

  Die Synthese von all-trans-Retinylamin und anderen Polyenaminen

  摘要：

  AbstractThe preparation of various polyene phthalimides using the azocarboxylate method is described. The imides are converted into the corresponding amines by reaction with hydrazine. In this way all‐trans‐retinylamine and β‐ionylamine have been obtained.

  DOI：

  10.1002/hlca.19730560523

文献信息

• Huisman et al., Recueil des Travaux Chimiques des Pays-Bas, 1952, vol. 71, p. 899,911
  作者：Huisman et al.

  DOI：——

  日期：——
• Azetidinone–retinoid hybrids: Synthesis and differentiative effects
  作者：Matteo Pori、Paola Galletti、Roberto Soldati、Laura Calzà、Chiara Mangano、Daria Giacomini

  DOI：10.1016/j.ejmech.2013.09.057

  日期：2013.12

  As a part of a systematic investigation on the synthesis and biological activities of new B-lactam compounds, we examined beta-lactam candidates 1, 2E and 2Z and their ability to induce cell proliferation or differentiation. Azetidinone 1 was chosen for its activity (previously evaluated) as selective HDAC8 inhibitor, whereas beta-lactams 2E and 2Z were designed to have a hybrid retinoid-azetidinone structure, de nova synthesized and fully characterized. Biological activities were determined in cellular assays on neuroblastoma cells SH-SY5Y. Azetidinone 1, 2E and 2Z led to a moderate effect in decreasing SH-SY5Y cell proliferation and beta-lactams 2E and 2Z induced an early stage differentiation.The present results uncovered a new role of specifically designed beta-lactam compounds in epigenetic regulation. (C) 2013 Elsevier Masson SAS. All rights reserved.
• COMPOSITIONS AND METHODS FOR TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
  申请人：Kubota Ryo

  公开号：US20090197967A1

  公开（公告）日：2009-08-06

  Provided herein are compositions and methods for treating ophthalmic diseases and disorders. Compositions comprising retinylamine derivative compounds provided herein are useful for treating and preventing ophthalmic diseases and disorders, including diabetic retinopathy diabetic maculopathy, diabetic macular edema, retinal ischemia, ischemia-reperfusion related retinal injury, and metabolic optic neuropathy.
• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT POUR MALADIES ET TROUBLES OPHTALMIQUES
  申请人：ACUCELA INC

  公开号：WO2007089673A2

  公开（公告）日：2007-08-09

  (EN) Provided herein are compositions and methods for treating ophthalmic diseases and disorders. Compositions comprising retinylamine derivative compounds provided herein are useful for treating and preventing ophthalmic diseases and disorders, including diabetic retinopathy diabetic maculopathy, diabetic macular edema, retinal ischemia, ischemia-reperfusion related retinal injury, and metabolic optic neuropathy.(FR) L'invention concerne des compositions et des méthodes pour traiter des maladies et des troubles ophtalmiques. Lesdites compositions comprennent des composés dérivés de la rétinylamine et sont utilisées pour traiter et prévenir des maladies et des troubles ophtalmiques, y compris une rétinopathie diabétique, une maculopathie diabétique, un œdème maculaire diabétique, une ischémie rétinienne, une lésion rétinienne d'ischémie de reperfusion, et une neuropathie optique métabolique.
• Matsui et al., Journal of Vitaminology, 1958, vol. 4, p. 190,192
  作者：Matsui et al.

  DOI：——

  日期：——